(Q30351034)

20 June 2017

title

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. (English)

1 reference

20 June 2017

5

Terrence M Tumpey

1 reference

20 June 2017

7

Gary J Nabel

1 reference

20 June 2017

2

Wing-pui Kong

1 reference

20 June 2017

Suzanne L Epstein

1

1 reference

20 June 2017

Julia A Misplon

series ordinal

3

1 reference

20 June 2017

Chia-Yun Lo

series ordinal

4

1 reference

20 June 2017

Ling Xu

series ordinal

6

1 reference

20 June 2017

language of work or name

English

0 references

publication date

13 June 2005

1 reference

20 June 2017

1 reference

20 June 2017

volume

23

1 reference

20 June 2017

issue

46-47

1 reference

20 June 2017

page(s)

5404-5410

1 reference

Control of influenza virus infection by immunity to conserved viral features.

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Development of a preventive vaccine for Ebola virus infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Replication-defective adenovirus type 5 as an in vitro and in vivo gene transfer vector in chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Resolution of Primary Murine Listeriosis and Acquired Resistance to Lethal Secondary Infection Can Be Mediated Predominantly by Thy-1+ CD4- CD8- Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

inferred from DOI database lookup

7 January 2021

based on heuristic

Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

inferred from DOI database lookup

7 January 2021

based on heuristic

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.047

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.04.047

1 reference

20 June 2017

1 reference